Palisade Bio (PALI) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palisade Bio (PALI) has outperformed Upstream Bio (UPB) over the past year, losing 27.5% versus a loss of 76.3%. Palisade Bio is the larger company by market cap ($268.4 million vs $257.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PALI | UPB |
|---|---|---|
| Share price | $1.54 | $4.70 |
| Market cap | $268.38M | $257.42M |
| 1-day change | +6.21% | +3.30% |
| YTD return | -38.30% | -82.69% |
| 1-year return | -27.50% | -76.25% |
| 5-year return | -99.93% | — |
| P/E ratio (TTM) | 2.57 | — |
| EPS (TTM) | $0.60 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.86 | $33.68 |
| 52-week low | $1.32 | $4.37 |
| Distance from 52-week high | -46.15% | -86.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +563.64% | +562.55% |
| Average volume | 2.56M | 647.42K |
| Shares outstanding | 174.27M | 54.77M |
| Employees | 14 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PALI has outperformed UPB by 48.8 percentage points over the past year.
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
PALI vs UPB FAQ
Which is bigger, Palisade Bio or Upstream Bio?
Palisade Bio (PALI) is larger, with a market capitalization of $268.38M compared with $257.42M for Upstream Bio (UPB).
Which stock has performed better over the past year, PALI or UPB?
PALI returned -27.50% over the past 12 months, compared with -76.25% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Palisade Bio and Upstream Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Palisade Bio and Biotechnology: Pharmaceutical Preparations for Upstream Bio.